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Abstract
EFSA asked the Panel on Dietetic Products, Nutrition and Allergies (NDA) to update the guidance on
the scientiﬁc requirements for health claims related to antioxidants, oxidative damage and
cardiovascular health published in 2011. The update takes into accounts experiences gained with
evaluation of additional health claim applications related to antioxidants, oxidative damage and
cardiovascular health, and the information collected from a Grant launched in 2014. This guidance is
intended to assist applicants in preparing applications for the authorisation of health claims related to
the antioxidants, oxidative damage and cardiovascular health. The document was subject to public
consultation (from 12 July to 3 September 2017). This document supersedes the guidance on the
scientiﬁc requirements for health claims related to antioxidants, oxidative damage and cardiovascular
health published in 2011. It is intended that the guidance will be further updated as appropriate in the
light of experience gained from the evaluation of health claims.
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Summary
The European Food Safety Authority (EFSA) has asked the Panel on Dietetic Products, Nutrition and
Allergies (NDA) to revise the guidance on the scientiﬁc requirements for health claims related to
antioxidants, oxidative damage and cardiovascular health published in 2011.
Since then, the NDA Panel has completed the evaluation of Article 13.1 claims (except for claims
put on hold by the European Commission) and has evaluated additional health claim applications
submitted pursuant to Articles 13(5), 14 and 19 which are in the area covered by this guidance. In
addition, the NDA Panel has developed the general scientiﬁc guidance for stakeholders for health
claims applications which addresses general issues that are common to all health claims. To further
assist applicants, EFSA launched in 2014 a grant which aimed at gathering information in relation to
claimed effects, outcome variables and methods of measurement in the context of the scientiﬁc
substantiation of health claims, and the information collected helped to inform the NDA Panel in
updating the present guidance.
This guidance is intended to assist applicants in preparing applications for the authorisation of
health claims related to the antioxidants, oxidative damage and cardiovascular health. It focuses on
key issues, particularly:
• claimed effects which are considered to be beneﬁcial physiological effects, and
• characteristics of the human intervention studies which can provide evidence for the scientiﬁc
substantiation of speciﬁc claims addressed in this guidance (e.g. appropriate outcome variables
and methods of measurement, suitable study group(s), appropriate duration of the study,
suitable controls).
This guidance does not intend to provide an exhaustive list of beneﬁcial physiological effects, or of
studies/outcome variables/methods of measurements which could be acceptable for claim
substantiation, or address potential health relationships and related outcome variables/methods of
measurement which have not yet been considered by the Panel in the context of a particular
application.
The guidance was subject to public consultation (from 12 July to 3 September 2017). This guidance
supersedes the guidance on the scientiﬁc requirements for health claims related to antioxidants,
oxidative damage and cardiovascular health published in 2011. It is intended that the guidance will be
further updated as appropriate in the light of experience gained from the evaluation of health claims.
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Background and Terms of Reference as provided by EFSA
Background
Regulation (EC) No 1924/20061 harmonises the provisions related to nutrition and health claims
and establishes rules governing the Community authorisation of health claims made on foods.
According to the Regulation, health claims should only be authorised for use in the Community after a
scientiﬁc assessment of the highest possible standard to be carried out by European Food Safety
Authority (EFSA).
Owing to the scientiﬁc and technical complexity of health claims, the EFSA Panel on Dietetic
Products, Nutrition and Allergies (NDA Panel) has placed considerable effort into developing scientiﬁc
criteria for the substantiation of health claims and has published guidance on the scientiﬁc
substantiation of health claims since 2007.2
In the last years, the NDA Panel has gained considerable experience in the evaluation of health
claim applications. To further assist applicants seeking approval of health claims, EFSA launched in
2014 a grant (GP/EFSA/NUTRI/2014/01) which aims at gathering information in relation to claimed
effects, outcome variables and methods of measurement in the context of the scientiﬁc substantiation
of health claims. The information collected will be published in a scientiﬁc report, which will help to
inform the NDA Panel and serve as a basis for further guidance to applicants. The format(s) under
which such guidance will be provided to applicants (e.g. guidance documents, and/or searchable,
interactive databases) will be carefully considered by EFSA.
In this context, note is taken of the need to adapt the existing guidance on the scientiﬁc
requirements for health claims to the new scientiﬁc and technical developments in speciﬁc areas taking
into account lessons learned from the evaluation of health claim applications and the information
collected from the grant.
To this end, the NDA Panel is asked to update the existing guidance on the scientiﬁc requirements
for health claims related to antioxidants, oxidative damage and cardiovascular (CV) health published in
2011.2
Terms of reference
The NDA Panel is requested by EFSA to update the existing guidance on the scientiﬁc requirements
for health claims related to antioxidants, oxidative damage and CV health.
The guidance document shall clarify and address the scientiﬁc and technical developments in this
area, taking into account the experience gained by the NDA Panel with the evaluation of health claims
and the information collected from the grant.
The draft guidance shall be released for public consultation prior to ﬁnalisation and shall be revised
taking into account the comments received during the public consultation before adoption by the NDA
Panel. A technical report on the outcome of the public consultation shall be published.
1. Introduction
The Guidance on the scientiﬁc requirements for health claims related to antioxidants, oxidative
damage and cardiovascular (CV) health (EFSA NDA Panel, 2011a), published in April 2011, laid down
recommendations on speciﬁc issues that need to be addressed in applications submitted for the
substantiation of health claims in this area. Since then, the European Food Safety Authority (EFSA)’s
Panel on Dietetic products, Nutrition and Allergies (NDA Panel) has evaluated additional health claim
applications related to antioxidants, oxidative damage and CV health.
Among the claim applications submitted to EFSA as of 17/2/2017, 59 were relevant to this guidance
(13 were withdrawn during the evaluation, 44 were evaluated/ﬁnalised by the NDA Panel and two were
under evaluation). Among those ﬁnalised,3 18 applications were evaluated by the Panel with a
favourable opinion: three related to claims on the protection of cells and molecules against oxidative
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
2 https://www.efsa.europa.eu/en/applications/nutrition/regulationsandguidance
3 Three were Article 13(5) claims (which are based on newly developed scientiﬁc evidence and/or which include a request for
the protection of proprietary data), three were Article 14 children claims, nine were Article 14 disease risk reduction claims,
and three were related to Article 19 applications for the modiﬁcation of existing authorisations of health claims.
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damage based on the essentiality of nutrients (on vitamin C,4 vitamin E5 and selenium6), 12 referred to
claims on CV health (on plant sterols,7 plant stanol esters,8 Danacol® low fat dairy product,9 oat beta-
glucans,10 barley beta-glucans,11 water-soluble tomato concentrate (WSTC),12 trans-free spreadable
fats,13 cocoa ﬂavanols,14 red yeast rice,15 Limicol®16) and three were requests for the modiﬁcation of
existing authorisations of health claims (on plant sterols and plant stanol esters,17 WSTC18 and cocoa
ﬂavanols19).
To further assist applicants, EFSA launched in 2014 a grant (GP/EFSA/NUTRI/2014/01) which aimed
at gathering information in relation to claimed effects, outcome variables and methods of
measurement in the context of the scientiﬁc substantiation of health claims.20 The information
collected helped to inform the NDA Panel for updating this guidance to applicants.
2. Objectives and scope
This guidance is intended to assist applicants in preparing applications for the scientiﬁc
substantiation of health claims related to antioxidants, oxidative damage and CV health.
The document focuses on key issues, particularly:
• claimed effects which are considered to be beneﬁcial physiological effects and
• characteristics of human intervention studies which can provide evidence for the scientiﬁc
substantiation of speciﬁc claims addressed in this guidance (e.g. appropriate outcome variables
and methods of measurement, suitable study group(s), appropriate duration of the study and
suitable controls).
Issues related to scientiﬁc substantiation that are common to all health claims (e.g. principles
applied for claims based on the essentiality of nutrients vs claims other than those based on the
essentiality of nutrients, aspects related to the characterisation of the food/constituent and to the
characterisation of the claimed effect, examples of the evidence required for the substantiation of
claims, criteria for the identiﬁcation of pertinent human studies) are addressed in the general scientiﬁc
guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016a) and will not be
reiterated in this document.
Examples of claims evaluated by the Panel with a favourable opinion will be used to provide
guidance to applicants on the scientiﬁc requirements for the substantiation of health claims in speciﬁc
areas, whereas examples of claims evaluated by the Panel with an unfavourable opinion will be used to
illustrate the shortcomings that prevented the substantiation of these claims.
The Panel, however, cannot provide guidance to applicants on the scientiﬁc requirements for the
substantiation of health claims (e.g. type of human intervention studies needed for substantiation) in
speciﬁc areas where no examples of favourable evaluations are available. This guidance does not
intend to provide an exhaustive list of beneﬁcial physiological effects or of studies/outcome variables/
methods of measurements, which could be acceptable for claim substantiation, or address potential
health relationships and related outcome variables/methods of measurement which have not yet been
considered by the Panel in the context of a particular application. The guidance will be kept under
review and will be amended and updated in the light of experiences gained from the evaluation of
additional health claim applications in this area.
4 Vitamin C (EFSA-Q-2008-175, Art 14(b)).
5 Vitamin E (EFSA-Q-2008-179, Art 14(b).
6 Selenium (EFSA-Q-2008-159, Art 14(b)).
7 Plant sterols (EFSA-Q-2008-085, Art 14(a)).
8 Plant stanol esters (EFSA-Q-2008-118, Art 14(a); EFSA-Q-2011-00851, Art 14(a)).
9 Danacol (EFSA-Q-2008-779, Art 14(a)).
10 Oat beta-glucan (EFSA-Q-2008-681, Art 14(a)).
11 Barley beta-glucan (EFSA-Q-2011-00798, Art 14(a); EFSA-Q-2011-00799, Art 14(a)).
12 Water-soluble tomato concentrate (EFSA-Q-2009-00229, Art 13(5)).
13 Trans free spreadable fats (EFSA-Q-2009-00458, Art 14(a)).
14 Cocoa ﬂavanols (EFSA-Q-2012-00002, Art 13(5)).
15 Red yeast rice (EFSA-Q-2012-00736, Art 13(5)).
16 Limicol® (EFSA-Q-2012-00968, Art 14(a)).
17 Plant sterols and plant stanol esters (EFSA-Q-2011-01241, Art 19).
18 Water-soluble tomato concentrate (EFSA-Q-2010-00809, Art 19).
19 Cocoa ﬂavanols (EFSA-Q-2013-00832, Art 19).
20 In the context of applications for authorisation of health claims under Articles 13.5 and 14 for which a Scientiﬁc Opinion had
been published up to the date of publication of the Grant (around 230 such Opinions had been published up to June 2014).
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This guidance should be read in conjunction with the General scientiﬁc guidance for stakeholders
on health claim applications (EFSA NDA Panel, 2016a), the Scientiﬁc and technical guidance for the
preparation and presentation of a health claim application (EFSA NDA Panel, 2017a), Regulation (EC)
No 1924/2006 on Nutrition and Health Claims made on foods,21 the Guidance on the implementation
of Regulation (EC) No 1924/2006 (Standing Committee on the Food Chain and Animal Health, 2007),
Commission Regulation (EC) No 353/200822, the Commission Implementing Decision of 24 January
2013,23 and future guidelines and regulations, as applicable.
3. Assessment
3.1. Function claims related to antioxidants and the protection of body
cells and molecules (i.e. proteins, lipids, DNA) from oxidative
damage, including photo-oxidative (UV-induced) damage
The protection of body cells and molecules such as proteins, lipids and DNA from oxidative
damage, including photo-oxidative (ultraviolet (UV)-induced) damage, is generally considered a
beneﬁcial physiological effect, assuming that any signiﬁcant oxidative modiﬁcation of the target
molecule is potentially harmful.
Claims made on the antioxidant content or properties of foods/constituents based on their
capability of scavenging free radicals in vitro refer to a property of the foods/constituents measured in
model systems, and it is not established that this capability exerts a beneﬁcial physiological effect in
humans as required by Regulation (EC) No 1924/2006.
Claims referring to antioxidant status and antioxidant defence have been proposed. The references
provided for the scientiﬁc substantiation of these claims included in vivo human studies which assessed
changes in the overall antioxidant capacity of plasma using methods such as the total reactive
antioxidant potential (TRAP), the trolox-equivalent antioxidant capacity (TEAC), the ferric reducing
antioxidant potential (FRAP), the oxygen radical absorbance capacity (ORAC) or ferrous oxidation–
xylenol orange (FOX) assays. It is not established that changes in the overall antioxidant capacity of
plasma exert a beneﬁcial physiological effect in humans as required by Regulation (EC) No 1924/2006.
Claims referring to the ‘protection of cells from premature ageing’ or to ‘healthy aging’ in relation to
the antioxidant properties of food/constituents are not sufﬁciently deﬁned for a scientiﬁc evaluation,
are considered to be general and non-speciﬁc and thus do not comply with the criteria laid down in
Regulation (EC) No 1924/2006.
3.1.1. Claims based on the essentiality of nutrients
Some vitamins and essential minerals have a role in the function of enzymes which belong to the
human antioxidant network that protects cells and molecules from oxidative damage. Claims on the
protection of DNA, proteins and lipids from oxidative damage related to vitamin C (EFSA NDA Panel,
2017b), vitamin E (EFSA NDA Panel, 2016b) and selenium (EFSA NDA Panel, 2014a) were evaluated
by the Panel with a favourable opinion. The scientiﬁc substantiation of these claims was based on the
essentiality of these nutrients,24 i.e. on the well-established biochemical role of such nutrients and/or
on deﬁciency symptoms involving in the human antioxidant network and/or the antioxidant defence
system. Their role in the human antioxidant network/the antioxidant defence system has been
established based on a large body of scientiﬁc evidence. For these claims, the NDA Panel did not
review the primary scientiﬁc studies submitted and it did not weigh the evidence.
21 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
CONSLEG:2006R1924:20100302:en:PDF
22 Commission Regulation (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation of
health claims as provided for in Article 15 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council
(Text with EEA relevance) (OJ L 109, 19.4.2008, p. 11): http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:
2008R0353:20091221:EN:PDF
23 Commission Implementing Decision of 24 January 2013 adopting guidelines for the implementation of speciﬁc conditions for
health claims laid down in Article 10 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council. OJ L
22, 25.1.2013, p. 25–28. Available at http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32013D0063
24 See General scientiﬁc guidance for stakeholders on health claim applications, Section 6.1
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2018;16(1):5136
Guidance for health claims related to antioxidants, oxidative damage and cardiovascular health
3.1.2. Claims other than those based on the essentiality of nutrients
In the context of an adequate supply of vitamins and essential minerals with a role in the function
of enzymes which belong to the human antioxidant network, induction of antioxidant enzymes cannot
be used alone as evidence for claims on the protection of cells and molecules from oxidative damage
for non-essential food constituents. The same principle applies to non-speciﬁc changes in the overall
antioxidant capacity of plasma.
A speciﬁc induction of antioxidant enzymes (e.g. superoxide dismutase (SOD), catalase (CAT),
glutathione peroxidase (GSH-Px), haem oxygenase (HO)), or limiting the decrease in glutathione and
glutathione/glutathione disulﬁde (GSH/GSSG) ratio, are considered to be a beneﬁcial physiological
effect only if such changes provide (additional) protection of cells and molecules from oxidative
damage. Such protection from oxidative damage should be demonstrated in vivo in humans. The same
principle applies to non-speciﬁc changes in the overall antioxidant capacity of plasma assessed in vivo
in humans using methods such as TRAP, FRAP, TEAC, ORAC or FOX assays.
The scientiﬁc substantiation of health claims on the protection of body cells and molecules from
oxidative damage, including photo-oxidative (UV-induced) damage, requires at least one appropriate
marker of oxidative modiﬁcation of the target molecule assessed in vivo in human studies (as deﬁned
in Sections 3.1.2.1–3.1.2.3), preferably in combination with other marker(s). These other markers of
oxidative damage to molecules cannot be used alone for substantiation, either because they represent
a result of two processes (oxidative damage and repair), because they suffer from technical limitations
(interferences from other unrelated processes or substances) or both. However, they can provide
supportive evidence for the scientiﬁc substantiation of these claims. Different markers of oxidative
damage to molecules should preferably be determined in the same study, but their determination in
similar studies could be acceptable on a case-by-case basis.
3.1.2.1. Protection of proteins from oxidative damage
Direct measurements of oxidative damage to proteins in vivo (e.g. measurement of oxidative
changes of amino acids in proteins) can be obtained by means of liquid chromatography-mass
spectrometry (LC-MS) and other methods, as long as identiﬁcation and separation of such molecules in
plasma from other substances is successfully achieved (e.g. from protein tyrosine nitration products).
Measures of protein oxidation products (e.g. protein carbonyls) using Enzyme-linked immunosorbent
assay (ELISA) methods (with an antidinitrophenyl (DNP) antibody after dinitrophenylhydrazine (DNPH)
derivatisation) can only be used in combination with at least one direct marker of oxidative damage to
proteins in vivo if assessed directly in blood or target tissue (e.g. skin). Conventional assays (e.g.
colorimetric assay involving DNPH derivatisation of carbonyl groups) can be used for plasma samples in
combination with at least one direct marker of oxidative damage to proteins in vivo.
3.1.2.2. Protection of lipids from oxidative damage
Direct measurements of oxidative damage to lipids (i.e. lipid peroxidation) can be obtained in vivo
by measuring changes in F2-isoprostanes in 24-h urine samples, which is a better matrix than plasma,
using appropriate chromatographic techniques coupled with mass spectrometry (e.g. gas
chromatography-mass spectrometry (GC-MS) or LC-MS). Immunological techniques, owing to their lack
of speciﬁcity due to possible cross reactions with other prostanoids, are not appropriate for measuring
F2-isoprostanes.
Measurements of oxidative damage to lipids (i.e. lipid peroxidation) can also be obtained in vivo by
measuring oxidised LDL particles (Ox-LDL) in blood using immunological methods (i.e. speciﬁc
monoclonal antibodies).
Lipid hydroperoxides (e.g. phosphatidylcholine hydroperoxides (PCOOH)) measured in blood or
tissue by chemiluminescence-based liquid chromatography (CL-LC) is also an acceptable marker of lipid
peroxidation in vivo. However, the combined measurement of PCOOH and F2-isoprostanes is
preferable.
Other outcome variables proposed are not reliable in vivo markers of lipid peroxidation (e.g.
thiobarbituric acid reactive substances (TBARS), malondialdehyde (MDA), HDL-associated paraoxonases,
conjugated dienes, breath hydrocarbons, autoantibodies against LDL particles and ex vivo LDL
resistance to oxidation). However, concentrations of MDA in blood or tissue can be used as supportive
evidence (i.e. in addition to measurements of F2-isoprostanes and/or in vivo LDL oxidation) if
appropriate techniques are used for MDA analysis (e.g. LC).
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3.1.2.3. Protection of DNA from oxidative damage
Direct measurements of oxidative damage to DNA (i.e. oxidised DNA bases) can be obtained in vivo
by using modiﬁcations of the comet assay (e.g. performed with endonuclease III to detect oxidised
pyrimidines and with formamidopyrimidine DNA glycosylase (FPG) to remove oxidatively damaged
purines). Although the assay provides no absolute values, it allows quantitative comparison with an
appropriate control. This assay directly reﬂects DNA oxidative damage within cells when assessed, for
example, in circulating lymphocytes.
Measures of DNA damage using the traditional comet assay (single-cell microgel electrophoresis,
SCGE), which detect DNA strand breaks by the appearance of tailing, are not speciﬁc for oxidative
damage. Other variants of the comet assay determine resistance against oxidative modiﬁcation using
ex vivo pro-oxidant challenges. Neither of these measurements are appropriate for assessing in vivo
oxidative damage to DNA.
Analyses of 8-hydroxy-2-deoxy-guanosin (8-OHdG) in blood (e.g. lymphocytes), tissue (e.g. skin)
and urine have been used to assess oxidative damage to DNA. Free 8-OHdG results from oxidative
damage and excision repair; it may also result from oxidation of free bases or nucleotides, from
oxidation of other nucleic acids and from artefacts during sample work up. Urinary 8-OHdG does not
directly reﬂect DNA oxidation within cells, but can be used in combination with direct measurements of
oxidative damage to DNA if appropriate techniques are used for analysis (e.g. LC).
3.2. Function claims related to the protection of DNA from strand breaks
DNA strand breaks occur spontaneously during the DNA repair process but can also be induced by
e.g. environmental factors (such as mutagenic or pro-oxidant chemicals, radiation). Such DNA strand
breaks alter DNA properties, may induce anomalies during DNA replication and translation and require
repair for maintenance of cell functioning and survival. Protection of DNA from strand breaks is a
beneﬁcial physiological effect.
Direct measurements of DNA strand breaks by the appearance of tailing can be obtained in vivo by
using the traditional comet assay (SCGE).
A health claim on the reduction of spontaneous DNA strand breaks has been evaluated by the
Panel with an unfavourable opinion (EFSA NDA panel, 2015). The Panel took into account that one
human intervention study showed that daily consumption of the food 4 weeks decreased spontaneous
DNA strand breaks, that no other human studies in which these results have been replicated were
provided and that no evidence was provided for a mechanism by which the food could exert the
claimed effect.
3.3. Function claims related to cardiovascular health
Claims referring to CV health in general are not sufﬁciently deﬁned for a scientiﬁc evaluation, as
they are considered to be general and non-speciﬁc, and thus do not comply with the criteria laid down
in Regulation (EC) No 1924/2006 unless they are accompanied by a speciﬁc claim. Examples of speciﬁc
claims are addressed in Sections 3.3.1–3.3.9 of this guidance.
A number of outcome variables have been proposed for the scientiﬁc substantiation of general
claims on CV health, including beneﬁcial changes in the blood lipid proﬁle, arterial blood pressure,
elastic properties of the arteries, endothelial function, plasma homocysteine concentrations, platelet
aggregation and venous blood ﬂow. Such outcome variables can be assessed in vivo in humans by
well-established methods and allow the scientiﬁc evaluation of speciﬁc function claims in the area of
CV health.
Evidence for a reduction in blood low-density lipoprotein (LDL)-cholesterol (LDL-c) concentrations is
sufﬁcient for the scientiﬁc substantiation of both function claims (i.e. on the maintenance of normal
blood LDL-c concentrations) and reduction of disease risk claims related, for example, to the risk of
coronary heart disease (CHD). The same applies to evidence for a reduction in arterial (systolic) blood
pressure (SBP) (see Section 3.4).
A reduction in the incidence of coronary events has also been proposed for the scientiﬁc
substantiation of function claims referring to CV health in general. Evidence for a reduction in the
incidence of coronary events (e.g. myocardial infarction) can be used alone for the substantiation of
function claims relating to the maintenance of normal cardiac function. However, such evidence is not
sufﬁcient for the scientiﬁc substantiation of reduction of disease risk claims in relation, for example, to
the risk of CHD, because evidence for a beneﬁcial alteration of one or more outcome variables (other
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than LDL-c and/or SBP) which can be considered as risk factors for the disease in the context of a
particular application is also needed (see Section 3.4).
3.3.1. Claims on maintenance of normal cardiac function
A function claim on eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and maintenance
of normal cardiac function have been evaluated by the Panel with a positive opinion (EFSA NDA Panel,
2010a).
The scientiﬁc basis for the substantiation of the claim was a wealth of human observational studies
showing a consistent association between the consumption of the food/constituent and a reduction in
the risk of CHD outcomes in the target population as well as human intervention studies showing an
effect of the food/constituent in reducing the risk of CHD outcomes in patients under medication (i.e.
secondary prevention).
3.3.2. Claims on a beneﬁcial change in the blood lipid proﬁle
A reduction in blood LDL-c concentrations (for claims on maintenance of normal blood
concentrations of LDL-c) and/or triglycerides (TG) and/or an increase in blood high-density lipoprotein
(HDL)-cholesterol (HDL-c) concentrations (as long as blood LDL-c concentrations are not increased) are
all considered beneﬁcial physiological effects. In this context, changes in the blood lipid proﬁle within
the normal range are also considered beneﬁcial physiological effects.
In principle, if a claim is best described by a number of outcome variables which are interrelated
(e.g. total cholesterol and LDL-c, LDL-c and HDL-c; TG and HDL-c), and which in combination could
provide information about the claim and eventually about the underlying mechanism of action, the
Panel will consider the information provided on all these variables to evaluate the claim. However, the
selection of the outcome variable(s) to be tested in a study and the decision to treat such variable(s)
as primary or as secondary outcomes would depend, among other considerations, on the study
objectives (e.g. exploratory, conﬁrmatory), the outcome variable(s) on which the power calculation
was based, the study group and the information which is already available (in the literature or to the
applicant) regarding the relationship between the consumption of the food/constituent and the claimed
effect (e.g. whether a mechanism of action by which the food/constituent could exert the claimed
effect is already known) (General scientiﬁc guidance, section 7.2.1).
The characterisation of the claimed effect for claims related to beneﬁcial changes in the blood lipid
proﬁle requires identiﬁcation of the particular marker(s) which should be considered for the scientiﬁc
evaluation (e.g. LDL-c, HDL-c, TG or a combination thereof).
The scientiﬁc evidence for the substantiation of health claims related to a beneﬁcial change in the
blood lipid proﬁle can be obtained from human intervention studies showing a reduction in LDL-c con-
centrations and/or an increase in HDL-c concentrations with a reduction or no change in LDL-c concentrations
and/or a reduction in blood TG concentrations as compared to an appropriate food/constituent or
exceptionally to no intervention (e.g. control group on usual diet).
All measurements should be performed using well-accepted methods and following standardised
conditions and protocols (e.g. Catapano et al., 2016). Particularly, it is important to standardise the
blood sampling conditions so that any differences from baseline between groups can be attributed to
the intervention rather than to the sampling conditions. In this context, non-fasting measurements of
the blood lipid proﬁle could be used for the scientiﬁc substantiation of these claims as long as the
conditions in which blood sampling is obtained are adequately standardised within the same study.
Regarding the study duration, blood lipids tend to stabilise after about 4 weeks in response to ﬁxed
nutritional interventions. However, the time needed to reach such stabilisation may depend on the
study characteristics (e.g. appropriate run-in period) and the nature of the intervention. Evidence on
the sustainability of the effect with continuous consumption of the food/constituent over longer
periods of time (e.g. 8 weeks) should be provided.
Claims for a beneﬁcial effect of the absence (or reduced content) of a food constituent in a food or
category of food on LDL-c concentration have been proposed. Substantiation may be based on
evidence for an independent role of the food constituent in increasing LDL-c concentration. For
example, for claims on a reduced content of saturated fatty acids (SFAs) in relation to blood LDL-c
concentration, SFAs in mixed diets have been shown to increase blood LDL-c concentration when
compared to carbohydrates which have a neutral effect on LDL-c concentration, and therefore, SFAs in
mixed diets have an independent role in increasing LDL-c concentration (EFSA NDA panel, 2011b).
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Claims for a beneﬁcial effect of a food constituent when used in replacement of a food constituent
with an independent role in increasing LDL-c concentration have also been proposed. Substantiation
may be based on evidence for an independent role of the replaced food constituent in increasing LDL-c
concentration, together with evidence for the lack of an effect or a reduced effect of the food
constituent which is used for replacement (e.g. claims for unsaturated fats and reduced LDL-c
concentration when replacing saturated fats) (EFSA NDA Panel, 2011c).
With respect to the study population, results from studies conducted in hypercholesterolaemic and/or
hypertriglyceridaemic subjects treated with lifestyle measures only (e.g. diet) could be used for the
scientiﬁc substantiation of these claims. However, the rationale for extrapolation of results obtained in
hypercholesterolaemic subjects under pharmacological treatment with cholesterol-lowering medications
(e.g. statins), and/or in hypertriglyceridaemic subjects under treatment with ‘triglyceride-lowering’
medications (e.g. ﬁbrates), to the target population for the claim should be provided and will be
considered on a case-by-case basis (e.g. evidence for a lack of interaction between the food and the
medications used on the claimed effect25).
3.3.3. Claims on the reduction of post-prandial blood concentration of
triglycerides
An increase in blood concentrations of TG after consumption of a fat-containing meal and/or food is
a normal physiological response that varies in magnitude and duration, and which may be inﬂuenced
by the chemical and physical nature of the food or meal consumed as well as by individual factors
(Jackson et al., 2012). Claims on the reduction of post-prandial blood concentrations of TG refer to the
ability of a food/constituent to reduce the blood TG rise after consumption of a food or meal rich in fat
(i.e. in comparison to a reference food or meal). A reduction of post-prandial blood concentrations of
TG is, in general, a beneﬁcial physiological effect for the adult population.
In principle, the scientiﬁc evidence for the substantiation of these claims can be obtained from
human intervention studies showing a reduction of post-prandial blood concentrations of TG at
different time points during an appropriate period of time after consumption of the test food in
comparison to the reference food. Generally, measurements should be taken for at least 4 h, with the
ﬁrst two measurements taken at 30 min and 60 min post-prandial, and every hour thereafter. The
Panel notes that there is no consensus on cut-off values to deﬁne normal post-prandial blood
concentrations of TG and that no standard protocols for the assessment are available yet (Kolovou
et al., 2011; Mihas et al., 2011). In this context, post-prandial blood concentrations of TG should be
measured under well-deﬁned and standardised conditions (Jagla and Schrezenmeir, 2001; Mihas et al.,
2011; Nordestgaard and Freiberg, 2011).
With respect to the study population, results from studies conducted in hypercholesterolaemic and/or
hypertriglyceridaemic subjects treated with lifestyle measures only (e.g. diet) could be used for the
scientiﬁc substantiation of these claims. However, the rationale for extrapolation of results obtained in
hypercholesterolaemic subjects under pharmacological treatment with cholesterol-lowering medications
(e.g. statins) and/or hypertriglyceridaemic subjects under treatment with ‘triglyceride-lowering’
medications (e.g. ﬁbrates) to the target population for the claim should be provided and will be
considered on a case-by-case basis (e.g. evidence for a lack of interaction between the food and the
medications used on the claimed effect25).
25 If subjects are under pharmacological treatment (whether or not for the claimed function/effect), the Panel considers whether
the effect of the food/constituent is also reasonably expected to occur in subjects without medication (e.g. evidence for a lack
of interaction between the food and the medications used on the claimed effect or evidence that the medication does not
affect the claimed effect as appropriate). For instance, cholesterol-lowering medications may also affect blood pressure. A lack
of interaction between a food/constituent and a medication on the claimed effect can be demonstrated when the mechanism
of action for both the food/constituent and the medication are known and different from each other. Whenever the
mechanism by which the food/constituent may exert the claimed effect is unknown, the default assumption is that an
interaction between the food/constituent and the medication used on the claimed effect exists, and therefore, the results
obtained in subjects under medication cannot be extrapolated to the target population for the claim (subjects not under
medication). Examples for a lack of interaction between the food/constituent and the medications used on the claimed effect
include plant sterols/stanols and statins on blood LDL-cholesterol concentrations as well as some dietary ﬁbres (e.g.
arabinoxylan, pectins) and some antidiabetic medications (e.g. metformin, insulin) on post-prandial blood glucose responses.
In both cases, the food/constituent (plant sterols/stanols, dietary ﬁbres) reduces or slows down the absorption of dietary fat
or glucose in the small intestine, whereas the medications (statins, some antidiabetic medications) affect either cholesterol or
glucose metabolism. Whenever the food/constituent and the medication act through the same (or similar) mechanisms, an
interaction can be expected.
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A health claim on the reduction of post-prandial lipaemic response has been evaluated by the
Panel with an unfavourable opinion (EFSA NDA Panel, 2013a) on the basis of the results of the only
study, from which conclusions could be drawn for the scientiﬁc substantiation of the claim, which did
not show an effect of the food/constituent on the reduction of post-prandial lipaemic responses.
3.3.4. Claims on the maintenance of normal (arterial) blood pressure
Maintenance of normal arterial blood pressure (BP) is a beneﬁcial physiological effect. The scientiﬁc
evidence for the substantiation of health claims on the maintenance of normal BP can be obtained
from human intervention studies showing a reduction in SBP (e.g. point SBP, 24-h SBP) or a reduction
in diastolic blood pressure (DBP) (e.g. point DBP, 24-h DBP) if accompanied by a reduction in SBP, as
compared to an appropriate food/constituent or exceptionally to no intervention (e.g. control group on
usual diet). In this context, also reductions in BP within the normal range are considered beneﬁcial
physiological effects.
Regarding the study duration, BP tends to stabilise after about 4 weeks in response to ﬁxed
nutritional interventions. However, the time needed to reach such stabilisation may depend on the
study characteristics (e.g. appropriate run-in period) and the nature of the intervention. Evidence on
the sustainability of the effect with continuous consumption of the food/constituent over longer
periods of time (e.g. 8 weeks) should be provided.
Studies should be designed to account for intraindividual variability, and BP should be measured
using well-accepted methods according to standardised conditions and protocols (Mancia et al., 2013).
Owing to the lack of standardisation, self (home) measurement of BP (e.g. using an electronic device)
is not an appropriate method for measuring point SBP and point DBP in research settings; validation of
the device and protocols used are required. Measurement with a calibrated sphygmomanometer (Mancia
et al., 2013; Tolonen et al., 2015)26 is the standard method for the assessment of ofﬁce BP.
Ambulatory blood pressure monitoring (ABPM) allows measuring BP over a 24-h period and
provides an insight to BP changes during everyday activities not covered by single measurements. The
ABPM is an appropriate method for measuring mean 24-h SBP and 24-h DBP.
With respect to the study population, results from studies conducted in hypertensive subjects
treated with lifestyle measures only (e.g. diet) could be used for the scientiﬁc substantiation of these
claims. However, the rationale for extrapolation of results obtained in hypertensive subjects under
treatment with blood pressure lowering medications (e.g. angiotensin converting enzyme (ACE)
inhibitors, blockers of beta adrenergic receptors, calcium channel blockers and diuretics) to the target
population for the claim should be provided and will be considered on a case-by-case basis (e.g.
evidence for a lack of interaction between the food and the medications used on the claimed effect25).
3.3.5. Claims on the maintenance of the elastic properties of the arteries
The elastic properties of conduit arteries vary along the arterial tree. The more elastic (compliant)
proximal arteries (e.g. the aorta and its primary branches) mainly attenuate blood ﬂow ﬂuctuations
generated by the intermittent pumping of the heart, whereas the more muscular distal arteries mainly
contribute to the propagation of the pressure wave. A decrease in the compliance (i.e. in the ability to
expand and contract in response to pressure changes through an increase in arterial stiffness) of the
big elastic arteries leads to an increase in mean blood pressure, with a disproportionate increase in
SBP and little changes in DBP, owing to both increased amplitude of the pressure wave and increased
wave velocity. Changes in the stiffness gradient of the arterial tree are observed with ageing,
hypertension and diabetes, among others. Maintenance of the elastic properties of the arteries is
considered a beneﬁcial physiological effect.
The scientiﬁc evidence for the substantiation of health claims on the maintenance of the elastic
properties of the arteries can be obtained from human intervention studies showing a reduction in
indices of arterial stiffness. Evidence on the sustainability of the effect with continuous consumption of
the food/constituent over extended periods of time (e.g. 4–8 weeks) should be provided.
Carotid–femoral pulse wave velocity (PWV) is the gold standard measurement of arterial stiffness.
Non-invasive determinations of wave reﬂections can also be obtained by central pulse wave analysis
through three major parameters: central pulse pressure, central systolic pressure and the
augmentation index (AIx). Central pressure, the AIx, and PWV cannot be used interchangeably as
indexes of arterial stiffness because, in contrast to PWV, which is a direct measure of arterial stiffness,
26 The sale of mercury sphygmomanometers has been banned since April 2014 (EU regulation 847/2012).
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2018;16(1):5136
Guidance for health claims related to antioxidants, oxidative damage and cardiovascular health
central pressure and the AIx are only indirect, surrogate measures of arterial stiffness. There is
consensus on the methodological aspects to be considered when measuring arterial stiffness in vivo in
humans (Laurent et al., 2006; Van et al., 2012).
A health claim on the maintenance of the elastic properties of the arteries, by measuring the
arterial stiffness, has been evaluated by the Panel with an unfavourable opinion (EFSA NDA Panel,
2009a) on the basis that, in addition to the methodological weaknesses of the study submitted for
substantiation, the study did not use a generally accepted method for the assessment of arterial
stiffness (calculated as ambulatory arterial stiffness index (AASI) from 24-h ABPM measurements).
3.3.6. Claims on the improvement of endothelial functions
Endothelial function per se is not sufﬁciently deﬁned for a scientiﬁc evaluation because endothelium-
derived active factors play a role in the maintenance of several functions of the vascular system. These
include vasomotion, smooth muscle proliferation, thrombosis, inﬂammation, coagulation, ﬁbrinolysis
and oxidation, which can be assessed by indirect methods. The characterisation of the claimed effect
requires identiﬁcation of the speciﬁc function which should be considered for the scientiﬁc evaluation
(e.g. endothelium-dependent vasodilation).
Some claims referred to the improvement of endothelium-dependent vasodilation, which is a speciﬁc
endothelial function that can be measured in vivo in humans using well-accepted methods. The capacity
of blood vessels to respond to physical and chemical stimuli in the lumen confers the ability to self-
regulate tone and to adjust blood ﬂow and distribution in response to changes in the local environment.
Many blood vessels respond to an increase in ﬂow or more precisely shear stress by dilating. This
phenomenon is designated as ﬂow-mediated dilation (FMD). A principal mediator of FMD is endothelium-
derived nitric oxide (NO). Endothelial denudation or treatment with a nitric oxide synthase (NOS)
inhibitor abolishes FMD in a variety of arterial vessels. Endothelium-derived prostanoids and the putative
endothelium-derived hyperpolarising factor have also been implicated as backup mechanisms mediating
changes in arterial diameter in response to shear stress, so that there may be some redundancy in the
system in order to ensure an appropriate response of blood vessels to shear stress. Endothelium-
dependent vasodilation contributes to the maintenance of an adequate blood ﬂow to body cells and
tissues (EFSA NDA Panel, 2012a).
Endothelium-dependent vasodilation can be assessed in vivo at different points of the arterial tree
(e.g. brachial artery) using well-established methods (e.g. the FMD technique27). Endothelium-
independent vasodilation (EIVD) of the brachial artery induced by exogenous NO donors (e.g. after the
sublingual administration of nitroglycerin) is also measured as control (Corretti et al., 2002; Thijssen
et al., 2011).
The effect of a food/constituent on endothelium-dependent vasodilation can be expressed as
changes in endothelium-dependent FMD (ED-FMD) either in fasting conditions after regular
consumption of the food/constituent or as acute changes in ED-FMD occurring shortly after
consumption of the food/constituent. A sustained increase in endothelium-dependent vasodilation in
fasting conditions in response to an intervention (regular consumption of a food/constituent for at least
4 weeks) is a beneﬁcial physiological effect.
Markers of plasma nitric oxide status (e.g. nitrite/nitrosyl species (RXNO) measured by reductive
gas-phase chemiluminescence) can provide evidence on the mechanisms by which the food/
constituent could exert the claimed effect but cannot be used alone for the substantiation of the claim.
Claims on maintenance of normal endothelium-dependent vasodilation response have been
evaluated by the Panel with a favourable opinion (e.g. cocoa ﬂavanols (EFSA NDA Panel, 2012a)). The
Panel took into account that cocoa ﬂavanols consumed for 12 weeks have been shown to increase
fasting ED-FMD signiﬁcantly in the target population in one human intervention study, that in another
study the effect was dose-dependent and occurred after 1 week of consumption, that the effect was
supported by two additional studies and that it was also observed in two of three studies in patients
under pharmacological treatment for coronary artery disease although the mechanisms by which
regular consumption of cocoa ﬂavanols may induce a sustained effect on fasting ED-FMD are unknown.
3.3.7. Claims on the reduction of platelet aggregation
Platelet hyperactivity and hypercoagulability states are more commonly observed in subjects with
CV risk factors. Healthy subjects at very low risk of CV disease normally have non-activated circulating
27 Corretti et al., 2002; Thijssen et al., 2011.
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platelets. A reduction in platelet aggregation (i.e. the percentage of inhibition in platelet aggregation
using light transmission aggregometry (LTA) according to well-accepted and standardised protocols28)
in subjects with platelet activation during sustained exposure to the food/constituent (at least
4 weeks) is a beneﬁcial physiological effect.
Other outcome variables, such as thromboxane A2 (TXA2), or plasma soluble P-selectin (P-sel), are
not well-established markers of platelet aggregation but can be used as supportive evidence for the
scientiﬁc substantiation of these claims.
A claim on maintenance of normal platelet aggregation has been evaluated by the Panel with a
favourable opinion (WSTC (EFSA, 2009a)), on the basis of: (i) a consistent effect of the
supplementation with WSTC on platelet aggregation which is sustained up to 28 days in subjects that
are representative of the target population for which the claim is intended and (ii) the biological
plausibility of this effect is supported by the presence of 37 identiﬁed compounds in aqueous tomato
extracts showing different degrees of inhibition of platelet aggregation in vitro and by the effects of
tomato extract on markers of platelet function in the animal study.
3.3.8. Claims on the maintenance of normal blood homocysteine concentrations
by contributing to normal homocysteine metabolism
Maintenance of normal homocysteine metabolism is a beneﬁcial physiological effect. It is well
established that homocysteine metabolism is closely linked with both folate metabolism and one-
carbon metabolism.
Evidence for the scientiﬁc substantiation of such a claim may come from the well-established role of a
food/constituent in contributing to the remethylation or degradation of homocysteine in the liver (e.g.
some vitamins), or from human intervention studies showing a reduction of homocysteine concentrations
(measured, for example, by liquid chromatography tandem mass spectrometry (LC-MS/MS)) as compared
to an appropriate food/constituent or exceptionally to no intervention (e.g. control group on usual
diet) or both.
Regarding the study duration, homocysteine concentrations tend to stabilise after about 4 weeks in
response to ﬁxed nutritional interventions. However, the time needed to reach such stabilisation may
depend on the study characteristics (e.g. appropriate run-in period) and the nature of the intervention.
Evidence on the sustainability of the effect with continuous consumption of the food/constituent over
longer periods of time (e.g. 8 weeks) should be provided.
Several claims on the maintenance of normal homocysteine metabolism, which have been
evaluated by the Panel with a favourable opinion, were based on the essentiality of nutrients (e.g.
folate (EFSA NDA Panel, 2009b), Vitamin B12 (EFSA NDA Panel, 2010b), Vitamin B6 (EFSA NDA Panel,
2010c)). Claims on betaine (and choline, which can be a precursor of betaine) were substantiated
taking into account that betaine can act as a methyl donor in the remethylation of homocysteine in the
liver by the enzyme betaine–homocysteine methyltransferase and that human intervention studies
consistently showed a signiﬁcant decrease in plasma homocysteine concentrations following betaine
(or choline) administration (EFSA NDA Panel, 2011d,e).
3.3.9. Venous blood ﬂow
Healthy veins contain bicuspid valves assisting unidirectional ﬂow from the lower limbs towards the
heart. The valves of the venous system may become incompetent and blood can ﬂow backwards
(venous reﬂux). Venous reﬂux is a pathological condition characterised by impaired return of blood and
increased venous pressure that may lead to venous stasis and eventually microangiopathy.
Maintenance of normal venous blood ﬂow is a beneﬁcial physiological effect. Blood ﬂow (e.g.
venous reﬂux) in blood vessels, including the veins, can be assessed in vivo by standard dynamic
ultrasound techniques (e.g. Duplex Doppler). The great saphenous diameter and the popliteal vein
diameter are per se not appropriate outcome variables for the substantiation of the claim.
Results from studies conducted in non-diseased population subgroups could be used for the
scientiﬁc substantiation of health claims on the maintenance of normal venous blood ﬂow. Information
on the selection criteria applied and on the characteristics of the study group in relation to the claimed
effect as well as a rationale for extrapolation of the results (e.g. subjects with chronic venous
insufﬁciency (CVI)) to the target population (healthy subjects without CVI) for which the claim is made
should be provided and will be considered on a case-by-case basis.
28 Cattaneo et al., 2013.
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Studies in patients with varicose veins and associated chronic venous diseases and which relate to
the treatment of symptoms of the disease cannot be considered for the scientiﬁc substantiation of
claims on venous function in the general population.
A health claim on the maintenance of normal venous blood ﬂow has been evaluated by the
Panel with an unfavourable opinion (e.g. EFSA NDA panel, 2012b) owing to the limited information
provided in relation to one study, and that the second study, which was conducted with a food not
complying with the characterisation of the food that is the subject of the claim, did not measure
venous blood ﬂow.
Also, health claims on the maintenance of normal physiological venous tone and the maintenance
of normal venous-capillary permeability have been proposed and were evaluated by the Panel with an
unfavourable opinion (e.g. EFSA NDA Panel, 2014b,c). The studies provided for the substantiation of
these claims included measurement of a reduction in the feeling of heaviness, burning, cramps and
formication in the lower limbs, which are not direct measures of ‘venous tone’, or measurement of the
changes of the volume of foot, ankle and leg, which is not a direct measure of ‘venous-capillary
permeability’.
3.4. Reduction of disease risk claims related to cardiovascular diseases
Regulation (EC) No 1924/2006 deﬁnes a ‘reduction of disease risk claim’ as any health claim that
states, suggests or implies that the consumption of a food category, a food or one of its constituents
signiﬁcantly reduces a risk factor in the development of a human disease. This is because health claims
referring to the reduction of the risk of a disease directly (i.e. to the prevention of a disease) cannot
be made on food. From a scientiﬁc perspective, the reduction in the risk of a disease (i.e. an effect of
the food/constituent on disease outcomes) provides stronger evidence for the substantiation of
reduction of disease risk claims than the reduction of a risk factor for the disease. However, evidence
on the reduction of the risk of a disease (e.g. coronary events) is not sufﬁcient for the substantiation
of these claims. Evidence that the consumption of the food/constituent also reduces (or beneﬁcially
affects) one or more risk factors for the disease should be provided to fulﬁl the requirements for the
wording of the claim laid down in Regulation (EC) No 1924/2006.
It is well established that elevated blood LDL-c concentration is independently associated with an
increased risk of CHD, and that reducing blood LDL-c concentration (by dietary modiﬁcation and/or
drugs) would generally reduce the risk of development of CHD. It is also well established that elevated
arterial SBP is independently associated with an increased risk of CHD and stroke, and that reducing
arterial SBP (by dietary modiﬁcation and/or drugs) would generally reduce the risk of development of
CHD and stroke. Therefore, the scientiﬁc substantiation of claims related to a decreased risk of CHD
can be based on evidence for a reduction of either blood LDL-c concentrations or arterial SBP, and
evidence for a reduction in the incidence of CHD is not required. Similarly, the scientiﬁc substantiation
of claims related to a decreased risk of stroke can be based on evidence for a reduction of arterial SBP,
and evidence for a reduction in the incidence of stroke is not required. In this context, blood LDL-c
concentrations and arterial SBP are the risk factors for CHD and/or stroke as required by Regulation
(EC) No 1924/2006.
Several disease risk reduction claims related to CHD risk which have proposed elevated LDL-c
concentrations as the risk factor for the disease have been evaluated by the Panel with a favourable
opinion (e.g. Limicol (EFSA NDA Panel, 2013b); Plant sterols (EFSA, 2008a); Plant stanol esters (EFSA,
2008b); Danacol® (EFSA, 2009b); Oat beta-glucan (EFSA NDA Panel, 2010d); Barley beta-glucan
(EFSA NDA Panel, 2011f); Trans-free spreadable fats (EFSA NDA Panel, 2011g)). The scientiﬁc
substantiation of all these claims has been based on evidence for a sustained reduction in LDL-c
concentrations with continuous consumption of the food/constituent, whereas evidence for a reduction
in the risk of the disease directly (i.e. on disease outcomes) has not been provided.
For proposed risk factors other than LDL-c and arterial SBP, the evidence on the relationship
between the risk factor and the development of the disease may not be as strong. There is some
evidence, for example, that low blood HDL-c concentration, elevated blood concentration of TG or
elevated blood homocysteine concentration are associated with an increased risk of CHD. However,
changes in any of these factors (by dietary modiﬁcation and/or drugs) have not generally been shown
to reduce the risk of CHD. Therefore, human studies on how the consumption of the food/constituent
prospectively modiﬁes the risk of CHD are required for the substantiation of these claims in order to
validate the association between these variables and the risk of disease in the context of a particular
nutritional intervention.
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Evidence for a reduction in the incidence of the disease (e.g. CHD, stroke) is necessary, but not
sufﬁcient, for the scientiﬁc substantiation of reduction of disease risk claims related to risk factors
other than LDL-c and arterial SBP. Evidence for a beneﬁcial alteration of one or more risk factors (e.g.
reduction in blood concentration of TG, reduction in blood homocysteine concentration or an increase
in blood HDL-c concentration) with the consumption of the food/constituent is also required.
A disease risk reduction claim related to the reduction of arterial stiffness by reducing the risk of
CVD has been evaluated by the Panel with an unfavourable opinion (EFSA, 2008c). It was considered
by the Panel that, in the context of the information provided at the time, arterial stiffness had an
independent predictive value for CV events in subjects with uncomplicated essential hypertension and
in the general population, among others. However, it had not been established that lowering arterial
stiffness can lower the risk of CVD. In this context, a reduction in arterial stiffness can be considered
as a risk factor in the development of the risk of CVD as long as evidence is provided that the
consumption of the food that is the subject of the health claim reduces the proposed risk factor as well
as the incidence of CVD.
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Glossary and Abbreviations
8-OHdG 8-hydroxy-2-deoxy-guanosin
AASI Ambulatory arterial stiffness index
ABPM Ambulatory blood pressure monitoring
ACE Angiotensin converting enzyme
AIx Augmentation index
CAT Catalase
CHD Coronary heart disease
CL-LC Chemiluminescence-based liquid chromatography
CV Cardiovascular
CVI Chronic venous insufﬁciency
DBP Diastolic blood pressure
DHA Docosahexaenoic acid
DNA Deoxyribonucleic acid
DNP Dinitrophenyl
DNPH Dinitrophenylhydrazine
ED-FMD Endothelium-dependent ﬂow-mediated dilation
EIVD Endothelium-independent vasodilation
ELISA Enzyme-linked immunosorbent assay
EPA Eicosapentaenoic acid
FMD Flow-mediated dilation
FOX Ferrous oxidation-xylenol orange
FPG Formamidopyrimidine DNA glycosylase
FRAP Ferric reducing antioxidant potential
GC-MS Gas chromatography-mass spectrometry
GSH/GSSG Glutathione/glutathione disulﬁde
GSH-Px Glutathione peroxidase
HO Haem oxygenase
HDL-c High-density lipoprotein cholesterol
LC Liquid chromatography
LC-MS Liquid chromatography-mass spectrometry
LC-MS/MS Liquid chromatography tandem mass spectrometry
LDL-c Low-density lipoprotein cholesterol
LTA Light transmission aggregometry
MDA Malondialdehyde
MS Mass spectrometry
NO Nitrite oxide
NOS Nitric oxide synthase
ORAC Oxygen radical absorbance capacity
Ox-LDL Oxidised LDL
PCOOH Phosphatidylcholine hydroperoxides
P-sel P-selectin
PWV Pulse wave velocity
RXNO Nitrite/nitrosyl species
SBP Systolic blood pressure
SCGE Single-cell microgel electrophoresis
SFA Saturated fatty acid
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SOD Superoxide dismutase
TBARS Thiobarbituric acid reactive substances
TEAC Trolox-equivalent antioxidant capacity
TG Triglyceride
TRAP Total reactive antioxidant potential
TXA2 Thromboxane A2
UV Ultraviolet
WSTC water-soluble tomato concentrate
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